Review
Biochemistry & Molecular Biology
Rashidah Baharudin, Nurul Qistina Rus Bakarurraini, Imilia Ismail, Learn-Han Lee, Nurul Syakima Ab Mutalib
Summary: Colorectal cancer is a major cause of cancer-related deaths worldwide, and microRNAs play a significant role in its occurrence and progression. However, the methylation profiles of microRNAs in colorectal cancer patients are still unknown. Methylation is an important factor in cancer detection, and this review aims to provide insight into the current understanding of microRNA methylation in colorectal cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Yiling Li, Kexin Li, Xiaoying Lou, Yue Wu, Samuel Seery, Danfei Xu, Yuqing Pei, Benheng Qian, Yuxin Wu, Shuang Liang, Kui Wu, Wei Cui
Summary: In this study, it was found that miR-92a in serum/plasma showed better diagnostic efficacy for colorectal cancer (CRC) compared to stool samples. Knockdown of HNRNPA2B1 resulted in decreased expression and secretion of miR-92a in CRC cells. The presence of common peaks of N6-methyladenosine (m6A) and HNRNPA2B1 in miR-92a indicated that HNRNPA2B1 mediated the expression of miR-92a through m6A modification. These findings suggest that blood-derived miR-92a could serve as a noninvasive biomarker for CRC and provide new insights into its mechanisms of expression and secretion.
Review
Health Care Sciences & Services
Mohammed Aref Kyyaly, Elena Vladimirovna Vorobeva, Dilini M. Kothalawala, Wei Chern Gavin Fong, Peijun He, Collin L. Sones, Mohammad Al-Zahrani, Tilman Sanchez-Elsner, Syed Hasan Arshad, Ramesh J. Kurukulaaratchy
Summary: This systematic review explores the potential of miRNAs as biomarkers for asthma diagnosis and severity-risk assessment. The review identifies multiple differentially expressed miRNAs, including two panels expressed in blood, which have the potential for further investigation.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Microbiology
Xiaopeng Li, Jiahui Feng, Zhanggui Wang, Gang Liu, Fan Wang
Summary: Colorectal cancer (CRC) is the third most common malignant tumor worldwide. A Chinese study investigated the composition of gut bacteria and fungi in healthy controls, CRC patients, CRA patients, and CRC postoperative patients. The analysis showed significant differences in beta diversity among the groups. Certain bacterial and fungal genera were found to be correlated in each group, and a negative correlation was observed between bacterial and fungal data. High levels of certain bacteria and fungi were detected in the feces of CRC patients compared to healthy controls. Further research is needed to understand the functional consequences of these microbial changes in CRC tumorigenesis.
FRONTIERS IN MICROBIOLOGY
(2023)
Review
Oncology
Farah J. Nassar, Zahraa S. Msheik, Rihab R. Nasr, Sally N. Temraz
Summary: Colorectal cancer is a deadly disease with a high mortality rate worldwide; early detection is crucial for improving survival outcomes; traditional CRC diagnostic tests have limitations, and methylated circulating tumor DNA shows promise as a potential biomarker worth further investigation.
CLINICAL EPIGENETICS
(2021)
Article
Gastroenterology & Hepatology
Jie Lin, Lijing Zhang, Mengshi Chen, Juan Chen, Yijuan Wu, Tao Wang, Yan Lu, Zhaofen Ba, Xiaowei Cheng, Rongrong Xu, Tian Tian, Aijuan Sun, Tiantian Zhang, Minghong Chen
Summary: The combined detection of fecal KRAS/BRAF/APC mutation and SFRP2/SDC2 methylation can serve as an auxiliary diagnostic approach for colorectal cancer and advanced adenoma, with high sensitivity and diagnostic specificity.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2022)
Article
Medical Laboratory Technology
Tao Shu, Kaiwen Wu, Yuanbiao Guo, Qiao He, Xiaoyu Song, Jing Shan, Liping Wu, Jia Liu, Zhiming Wang, Lei Liu, Xiaobin Sun
Summary: The study found that fecal synaptophysin like 1 (fSYPL1) has high sensitivity and specificity for colorectal cancer (CRC) screening, and is positively correlated with tumor size, invasion, lymph node invasion, and clinical stage. It has a high detection rate for early CRC and the fSYPL1 levels decline after surgery. The combination of fSYPL1 and FOBT performs better in distinguishing CRC patients from controls.
CLINICAL BIOCHEMISTRY
(2022)
Article
Oncology
Xiao-Han Fan, Yang Zhang, Pei Wang, Qian-Qian Song, Mona Wang, Raquel Mejias-Luque, Zhe-Xuan Li, Tong Zhou, Jing-Ying Zhang, Wei-Dong Liu, Lan-Fu Zhang, Wen-Qing Li, Wei-Cheng You, Markus Gerhard, Yu-Chen Jiao, Xiao-Bing Wang, Kai-Feng Pan
Summary: This study explores noninvasive multianalytical biomarkers and constructs integrative models for risk assessment and gastric cancer (GC) screening. Methylation, mutation, and H. pylori-specific antibody panels were established and validated, and integrated models incorporating these biomarkers outperformed traditional models for risk assessment and GC detection. This study provides new insights for a more precise GC screening strategy in the future.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Rong-Qiang Yuan, Hui Zhao, Yan Wang, Kai Song, Jia Yang, Wei He, Da-Zhuang Miao, Qi Wang, Yun-He Jia
Summary: This study developed a minimally invasive blood-based test for detection of precancerous lesions and early-stage colorectal cancer (CRC). By analyzing methylation data, a 3-gene methylation signature model with high accuracy for CRC diagnosis was established. The model demonstrated superior performance in public databases and blood samples, showing potential for clinical application in improving early diagnosis of CRC.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Oncology
Rong-Qiang Yuan, Hui Zhao, Yan Wang, Kai Song, Jia Yang, Wei He, Da-Zhuang Miao, Qi Wang, Yun-He Jia
Summary: A minimally invasive blood-based test for the detection of precancerous lesions and early-stage CRC has been developed with high accuracy. The proposed 3-gene methylation signature shows superior performance and has the potential for clinical application.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Review
Oncology
Shunhao Zhang, Jing Sun, Minqi Gu, Guihua Wang, Xudong Wang
Summary: Circular RNAs, a special type of noncoding RNA, exhibit high stability and potential gene regulation effects, playing roles in various biological functions and showing associations with the development and chemotherapy resistance of CRC.
Article
Oncology
Chi T. Viet, Xinyu Zhang, Ke Xu, Gary Yu, Kesava Asam, Carissa M. Thomas, Nicholas F. Callahan, Coleen Doan, Paul C. Walker, Khanh Nguyen, Stephanie C. Kidd, Steve C. Lee, Anupama Grandhi, Clint T. Allen, Simon Young, James C. Melville, Jonathan W. Shum, Dan T. Viet, Alan S. Herford, Dylan F. Roden, Manuel L. Gonzalez, Jiang F. Zhong, Bradley E. Aouizerat
Summary: This study utilized MethylCap-Seq technique along with brush swab samples to develop a non-invasive methylation profiling method in oral squamous cell carcinoma patients. The results demonstrated that brush swab samples provide adequate DNA yield and methylation resolution comparable to tissue samples, indicating a promising approach for methylome studies in OSCC patients.
BIOMARKER RESEARCH
(2021)
Article
Gastroenterology & Hepatology
Qian-Qian Wang, Lei Zhou, Geng Qin, Chang Tan, Yuan-Chen Zhou, Shu-Kun Yao
Summary: LILRB2 expression is significantly associated with advanced stage and poor prognosis in CRC, making it a potential therapeutic target and noninvasive screening biomarker for the disease.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Oncology
Goli Siri, Samira Alesaeidi, Saeed Esmaeili Dizghandi, Behrang Alani, Meysam Mosallaei, Mohsen Soosanabadi
Summary: This study aimed to evaluate the noninvasive early diagnosis of colorectal cancer (CRC) through quantitative promoter methylation analysis of the SDC2 gene in whole blood. The findings demonstrate that SDC2 promoter methylation in blood samples is a valuable biomarker for CRC diagnosis, with high sensitivity and specificity. The methylation level of SDC2 also correlates with tumor progression, making it a useful tool for detecting early stages of CRC.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
(2022)
Article
Oncology
Wu-Hao Lin, Jian Xiao, Zi-Yi Ye, Da-Liang Wei, Xiao-Hui Zhai, Rui-Hua Xu, Zhao-Lei Zeng, Hui-Yan Luo
Summary: This study validated the potential of MYO1-G as a biomarker for diagnosis and monitoring of CRC, showing high accuracy in discriminating CRC patients and association with tumor burden and treatment response.
CLINICAL EPIGENETICS
(2021)